

Onxeo S.A. Secures \$7.5 Million of Non-Dilutive Capital from SWK Holdings Corporation Through the Partial Sale of Future Beleodaq® Royalties

Torreya served as financial advisor to Onxeo in the transaction

Paris, France, June 7, 2018

Onxeo S.A., a biotechnology company specializing in the development of innovative drugs against rare or resistant forms of cancer, today announced that it has entered into a royalty agreement with SWK Holdings Corporation, a US life science focused specialty finance company. Under the terms of the transaction, Onxeo will receive an upfront amount of \$7.5 million through the issuance of bonds entitling SWK to receive up to \$13.5 million of future royalties and milestones on net sales of Beleodaq® (belinostat) in territories licensed to Spectrum Pharmaceuticals, Inc.

This non-dilutive capital extends Onxeo's cash runway through early 2020, and helps drive the development of Onxeo's key programs, notably AsiDNATM, through multiple significant inflection points over the next 12 to 18 months.

Torreya's Capital Markets team served as financial advisor to Onxeo in the financing. Our team continues to be dedicated to raising capital for our corporate clients via structured transactions and royalty monetizations. This is our eighth royalty deal since the start of 2016. Torreya has advised on over 36 strategic and financing transactions in the life sciences industry in the last 18 months.

ABOUT ONXEO S.A.

For more information about Onxeo, please see: www.onxeo.com

ABOUT SWK HOLDINGS CORPORATION

For more information about SWK Holdings, please see: www.swkhold.com

Deal Press Release

Torreya Contact

ANNA A. MAKKI

Managing Director | New York Office

anna.makki@torreya.com | 212.257.5825 | torreya.com



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.